Cost-effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-COVID-19 condition after hospitalisation for COVID-19: the REGAIN RCT.
COVID-19
Cost-effectiveness analysis
Cost-utility analysis
Long COVID
Mental health rehabilitation
Physical rehabilitation
Post-COVID-19 condition
RCT
Randomised controlled trials
Rehabilitation
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
04
03
2024
accepted:
30
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Following the COVID-19 pandemic, millions of people continue to experience ongoing physical and mental health sequelae after recovery from acute infection. There is currently no specific treatment for the diverse symptoms associated with post-COVID-19 condition. Physical and mental health rehabilitation may help improve quality of life in such patients. This study reports the cost-effectiveness of a programme of physical and mental health rehabilitation compared to best practice usual care in people with post-COVID-19 condition who were previously hospitalised. We conducted an economic evaluation within a randomised controlled trial from the perspective of the UK national health service (NHS) and personnel social services perspective (PSS). Resource used and health-related quality of life were collected using bespoke questionnaire and the EQ-5D-5 L questionnaire at three, six, and 12 months. Incremental costs and quality adjusted life years accrued over the follow-up period were estimated and reported as the incremental cost-effectiveness ratio. Estimate uncertainty was managed by multiple imputation and bootstrapping cost-effectiveness estimates; and displayed graphically on the cost-effectiveness plane. Over a 12-month time horizon, incremental costs and QALYs were £305 (95% CI: -123 to 732) and 0.026 (95% CI: -0.005 to 0.052) respectively. The ICER was £11,941 per QALY indicating cost-effective care. Sensitivity analyses supported the base case findings. The probability of the intervention being cost-effective at a £30,000 per QALY willingness-to-pay threshold was 84%. The within-trial economic evaluation suggested that people with post-COVID-19 condition after hospitalisation should be offered a programme of physical and mental health rehabilitation as it likely reflects a cost-effective use of NHS resources. Hospitalisation for COVID-19 has become less commonplace: further evaluation in non-hospitalised patients may be worthwhile. ISRCTN registry ISRCTN11466448 23rd November 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Following the COVID-19 pandemic, millions of people continue to experience ongoing physical and mental health sequelae after recovery from acute infection. There is currently no specific treatment for the diverse symptoms associated with post-COVID-19 condition. Physical and mental health rehabilitation may help improve quality of life in such patients. This study reports the cost-effectiveness of a programme of physical and mental health rehabilitation compared to best practice usual care in people with post-COVID-19 condition who were previously hospitalised.
METHODS
METHODS
We conducted an economic evaluation within a randomised controlled trial from the perspective of the UK national health service (NHS) and personnel social services perspective (PSS). Resource used and health-related quality of life were collected using bespoke questionnaire and the EQ-5D-5 L questionnaire at three, six, and 12 months. Incremental costs and quality adjusted life years accrued over the follow-up period were estimated and reported as the incremental cost-effectiveness ratio. Estimate uncertainty was managed by multiple imputation and bootstrapping cost-effectiveness estimates; and displayed graphically on the cost-effectiveness plane.
RESULTS
RESULTS
Over a 12-month time horizon, incremental costs and QALYs were £305 (95% CI: -123 to 732) and 0.026 (95% CI: -0.005 to 0.052) respectively. The ICER was £11,941 per QALY indicating cost-effective care. Sensitivity analyses supported the base case findings. The probability of the intervention being cost-effective at a £30,000 per QALY willingness-to-pay threshold was 84%.
CONCLUSION
CONCLUSIONS
The within-trial economic evaluation suggested that people with post-COVID-19 condition after hospitalisation should be offered a programme of physical and mental health rehabilitation as it likely reflects a cost-effective use of NHS resources. Hospitalisation for COVID-19 has become less commonplace: further evaluation in non-hospitalised patients may be worthwhile.
TRIAL REGISTRATION
BACKGROUND
ISRCTN registry ISRCTN11466448 23rd November 2020.
Identifiants
pubmed: 39482691
doi: 10.1186/s12913-024-11679-5
pii: 10.1186/s12913-024-11679-5
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326Subventions
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Organisme : National Institute for Health and Care Research
ID : NIHR132046
Informations de copyright
© 2024. The Author(s).
Références
Raveendran A, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metabolic Syndrome: Clin Res Reviews. 2021;15(3):869–75.
doi: 10.1016/j.dsx.2021.04.007
Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.
doi: 10.1038/s41579-022-00846-2
pubmed: 36639608
pmcid: 9839201
Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. 2023 [cited 2024 14/02]; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023 .
UK Health Security Agency. COVID-19 Hospital Activity. 2024. [cited 2024 05/09]. Available from: https://ukhsa-dashboard.data.gov.uk/topics/covid-19 .
Evans RA, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK Multicentre, prospective cohort study. Lancet Respiratory Med. 2021;9(11):1275–87.
doi: 10.1016/S2213-2600(21)00383-0
O'Mahoney LL, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.
Cha C, Baek G. Symptoms and management of long COVID: a scoping review. J Clin Nurs. 2024;33(1):11–28.
doi: 10.1111/jocn.16150
pubmed: 34913540
Huizinga F, et al. Home-based physical activity to alleviate fatigue in cancer survivors: a systematic review and meta-analysis. Med Sci Sports Exerc. 2021;53(12):2661.
doi: 10.1249/MSS.0000000000002735
pubmed: 34649267
pmcid: 8594505
Organization WH. 2015 global survey on health technology assessment by national authorities: main findings, in 2015 global survey on health technology assessment by national authorities: main findings. 2015.
McGregor G, et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial. BMJ. 2024;384:e076506.
doi: 10.1136/bmj-2023-076506
pubmed: 38325873
pmcid: 11134408
McGregor G, et al. Rehabilitation Exercise and psycholoGical support after covid-19 InfectioN’(REGAIN): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):1–3.
British National Formulary. British National Formulary. 2022;81. [cited 2022 01/12]. Available from: https://bnf.nice.org.uk/ .
Ennis S, et al. Development of an online intervention for the Rehabilitation Exercise and psycholoGical support after covid-19 InfectioN (REGAIN) trial. NIHR Open Res. 2023;3:10.
doi: 10.3310/nihropenres.13371.2
pubmed: 37881468
pmcid: 10593321
NHS Improvement, NHS Improvement. Highlights, analysis and introduction to the data, in 2021/22 National Cost Collection Data Publication, National Health Service England. 2022.
National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. 2013.
Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, Forder JE, Gao J, Hinde S, Markham S, Ogunleye D. Unit Costs of Health and Social Care 2022 Manual. Technical report. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York), Kent. 2023. https://doi.org/10.22024/UniKent/01.02.100519 .
NHS Business Services Authority. Prescription Cost Analysis-England. 2022. [cited 2023 02/02]. Available from: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-cost-analysis-england-202122 .
Office for National Statistics. Employee earnings in the UK: 2021. London: Office for National Statistics; 2021.
Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
doi: 10.1007/s11136-011-9903-x
pubmed: 21479777
pmcid: 3220807
Van Hout B, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.
doi: 10.1016/j.jval.2012.02.008
pubmed: 22867780
Hernández Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK Population Study. Pharmacoeconomics. 2023;41(2):199–207.
doi: 10.1007/s40273-022-01218-7
pubmed: 36449173
National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L value set for England (updated October. 2019). 2019; https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l .
Gomes M, et al. Multiple imputation methods for handling missing data in cost-effectiveness analyses that use data from hierarchical studies: an application to cluster randomized trials. Med Decis Making. 2013;33(8):1051–63.
doi: 10.1177/0272989X13492203
pubmed: 23913915
StataCorp. College Station, TX: StataCorp LP; 2023. Stata Stat Software: Release. 2023;19:19.
Faria R, et al. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics. 2014;32(12):1157–70.
doi: 10.1007/s40273-014-0193-3
pubmed: 25069632
pmcid: 4244574
Madley-Dowd P, et al. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63–73.
doi: 10.1016/j.jclinepi.2019.02.016
pubmed: 30878639
pmcid: 6547017
Little RJ, Rubin DB. Statistical analysis with missing data, vol. 793. College Station: John Wiley & Sons; 2019.
Grishechkina IA, Lobanov AA, Andronov SV, Rachin AP, Fesyun AD, Ivanova EP, Masiero S, Maccarone MC. Long-term outcomes of different rehabilitation programs in patients with long COVID syndrome: a cohort prospective study. Eur J Transl Myol. 2023;33(2):11063. https://doi.org/10.4081/ejtm.2023.11063 .
Nopp S, et al. Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life. Respiration. 2022;101(6):593–601.
doi: 10.1159/000522118
pubmed: 35203084
Compagno S, et al. Physical and psychological reconditioning in long COVID syndrome: results of an out-of-hospital exercise and psychological-based rehabilitation program. IJC Heart Vasculature. 2022;41:101080.
doi: 10.1016/j.ijcha.2022.101080
pubmed: 35854691
pmcid: 9286763
Jimeno-Almazán A, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial. Scand J Med Sci Sports. 2022;32(12):1791–801.
doi: 10.1111/sms.14240
pubmed: 36111386
Longobardi I, et al. Effects of a 16-week home-based exercise training programme on health-related quality of life, functional capacity, and persistent symptoms in survivors of severe/critical COVID-19: a randomised controlled trial. Br J Sports Med. 2023;57(20):1295–303.
doi: 10.1136/bjsports-2022-106681
pubmed: 37164620
Berentschot JC, Heijenbrok-Kal MH, Bek LM, Huijts SM, van Bommel J, van Genderen ME, Aerts JGJV, Ribbers GM, Hellemons ME, van den Berg-Emons RJG; CO-FLOW Collaboration Group. Physical recovery across care pathways up to 12 months after hospitalization for COVID-19: A multicenter prospective cohort study (CO-FLOW). Lancet Reg Health Eur. 2022;22:100485. https://doi.org/10.1016/j.lanepe.2022.100485 .
Sánchez-García JC, Reinoso-Cobo A, Piqueras-Sola B, Cortés-Martín J, Menor-Rodríguez MJ, Alabau-Dasi R, Rodríguez-Blanque R. Long COVID and Physical Therapy: a Systematic Review. Diseases. 2023;11(4):163. https://doi.org/10.3390/diseases11040163 .
Melendez-Oliva E, et al. Efficacy of pulmonary rehabilitation in post-COVID-19: a systematic review and meta-analysis. Biomedicines. 2023;11(8):2213.
doi: 10.3390/biomedicines11082213
pubmed: 37626710
pmcid: 10452542
Erku D, Khatri R, Endalamaw A, Wolka E, Nigatu F, Zewdie A, Assefa Y. Digital Health Interventions to Improve Access to and Quality of Primary Health Care Services: a scoping review. Int J Environ Res Public Health. 2023;20(19):6854. https://doi.org/10.3390/ijerph20196854 .
Khan N, et al. Post-COVID-19: can digital solutions lead to a more equitable global healthcare workforce? BJPsych Int. 2023;20(1):18–23.
doi: 10.1192/bji.2022.12
pubmed: 36812032
pmcid: 9909439
Clinical management of COVID-19: living guideline, 13 January 2023. Geneva: World Health Organization; 2023. (WHO/2019-nCoV/clinical/2023.1). Licence: CC BY-NC-SA 3.0 IGO.
Pichon-Riviere A, et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Global Health. 2023;11(6):e833–42.
doi: 10.1016/S2214-109X(23)00162-6
pubmed: 37202020
Collaborators G. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15.
doi: 10.1001/jama.2022.18931
Cutler DM. The economic cost of long COVID: an update. Publish Online July; 2022.